<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article  PUBLIC "-//NLM//DTD Journal Publishing DTD v3.0 20080202//EN" "http://dtd.nlm.nih.gov/publishing/3.0/journalpublishing3.dtd"><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="3.0" xml:lang="en" article-type="research article"><front><journal-meta><journal-id journal-id-type="publisher-id">ACM</journal-id><journal-title-group><journal-title>Advances in Clinical Medicine</journal-title></journal-title-group><issn pub-type="epub">2161-8712</issn><publisher><publisher-name>Scientific Research Publishing</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.12677/ACM.2020.109301</article-id><article-id pub-id-type="publisher-id">ACM-37669</article-id><article-categories><subj-group subj-group-type="heading"><subject>ACM20200900000_67972165.pdf</subject></subj-group><subj-group subj-group-type="Discipline-v2"><subject>医药卫生</subject></subj-group></article-categories><title-group><article-title>
 
 
  UA、NLR对急性心肌梗死患者PCI术后预后的判断价值的研究
  The Value of UA NLR in Predicting the Prognosis of Patients with Acute Myocardial Infarction after PCI
 
</article-title></title-group><contrib-group><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>徐</surname><given-names>宝丽</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>李</surname><given-names>喆</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>管</surname><given-names>甲亮</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>臧</surname><given-names>守亚</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>刘</surname><given-names>艳伟</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>李</surname><given-names>菁</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>王</surname><given-names>星月</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>周</surname><given-names>长勇</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib></contrib-group><aff id="aff2"><addr-line>青岛大学附属医院急诊内科，山东 青岛</addr-line></aff><aff id="aff1"><addr-line>null</addr-line></aff><pub-date pub-type="epub"><day>08</day><month>09</month><year>2020</year></pub-date><volume>10</volume><issue>09</issue><fpage>2009</fpage><lpage>2016</lpage><permissions><copyright-statement>&#169; Copyright  2014 by authors and Scientific Research Publishing Inc. </copyright-statement><copyright-year>2014</copyright-year><license><license-p>This work is licensed under the Creative Commons Attribution International License (CC BY). http://creativecommons.org/licenses/by/4.0/</license-p></license></permissions><abstract><p>
 
 
  
    高中性粒细胞与淋巴细胞之比(neutrophil to lymphocyte ratio, NLR)和尿酸(uric acid, UA)的结合将更强地预测经皮冠状动脉介入治疗(percutaneous coronary intervention, PCI)后未来的心血管事件。在148例接受PCI的连续患者中测量了NLR和UA。主要终点是主要的不良心血管事件(major adverse cardiovascular Events, MACE)的发生率，包括心源性死亡、充血性心力衰竭、反复缺血性发作性心绞痛、再发心肌梗死、非计划再次血运重建、心源性再次住院、恶性心律失常。NLR和UA的中位数分别为4.89和344.71。在12个月的随访期间有45例MACE。数据分析显示，较高的NLR以及较高的UA组的MACE率明显高于较低的NLR组和/或较低的UA组。NLR和UA的组合可进一步增加MACE发生率的预测准确性。该值在急性心肌梗死(acute myocardial infarction, AMI)患者中特别有用。通过多变量Cox比例风险模型，高NLR和高UA的组合与MACE独立相关(P &lt; 0.05)。高NLR和高UA的组合是PCI后MACE的独立预测指标，尤其是AMI患者。
    We hypothesized that the combination of neutrophil to lymphocyte ratio (NLR) and uric acid (UA) is a better predictor of future cardiovascular events after percutaneous coronary intervention (PCI). NLR and UA were measured in 148 consecutive patients undergoing PCI. The primary endpoint was the incidence of major adverse cardiovascular events (MACE), including cardiac death, congestive heart failure, recurrent ischemic attack angina, recurrent myocardial infarction, unplanned revascularization, cardiogenic readmission, and malignant arrhythmia. The median of NLR and UA were 4.89 and 344.71, respectively. During the 12-month follow-up period, there were 45 cases of MACE. Data analysis showed that the MACE rate of higher NLR group and higher UA group was significantly higher than that of lower NLR group and/or lower UA group. The combination of NLR and UA can further improve the prediction accuracy of MACE incidence. This value is particularly useful in patients with acute myocardial infarction (AMI). By multivariate Cox proportional hazard model, the combination of high NLR and high UA was independently associated with MACE (P &lt; 0.05). The combination of high NLR and high UA is an independent predictor of MACE after PCI, especially in patients with AMI. 
  
 
</p></abstract><kwd-group><kwd>中性粒细胞与淋巴细胞的比率，尿酸，经皮冠状动脉介入治疗，MACE, Neutrophil to Lymphocyte Ratio</kwd><kwd> Uricacid</kwd><kwd> Percutaneous Coronary Intervention</kwd><kwd> MACE</kwd></kwd-group></article-meta></front><body><sec id="s1"><title>摘要</title><p>高中性粒细胞与淋巴细胞之比(neutrophil to lymphocyte ratio, NLR)和尿酸(uric acid, UA)的结合将更强地预测经皮冠状动脉介入治疗(percutaneous coronary intervention, PCI)后未来的心血管事件。在148例接受PCI的连续患者中测量了NLR和UA。主要终点是主要的不良心血管事件(major adverse cardiovascular Events, MACE)的发生率，包括心源性死亡、充血性心力衰竭、反复缺血性发作性心绞痛、再发心肌梗死、非计划再次血运重建、心源性再次住院、恶性心律失常。NLR和UA的中位数分别为4.89和344.71。在12个月的随访期间有45例MACE。数据分析显示，较高的NLR以及较高的UA组的MACE率明显高于较低的NLR组和/或较低的UA组。NLR和UA的组合可进一步增加MACE发生率的预测准确性。该值在急性心肌梗死(acute myocardial infarction, AMI)患者中特别有用。通过多变量Cox比例风险模型，高NLR和高UA的组合与MACE独立相关(P &lt; 0.05)。高NLR和高UA的组合是PCI后MACE的独立预测指标，尤其是AMI患者。</p></sec><sec id="s2"><title>关键词</title><p>中性粒细胞与淋巴细胞的比率，尿酸，经皮冠状动脉介入治疗，MACE</p></sec><sec id="s3"><title>The Value of UA NLR in Predicting the Prognosis of Patients with Acute Myocardial Infarction after PCI</title><p>Baoli Xu, Zhe Li, Jialiang Guan, ShouyaZang, Yanwei Liu, Jing Li, Xingyue Wang, Changyong Zhou<sup>*</sup></p><p>Department of Emergency Medicine, Affiliated Hospital of Qingdao University, Qingdao Shandong</p><p><img src="//html.hanspub.org/file/21-1571557x5_hanspub.png" /></p><p>Received: Aug. 26<sup>th</sup>, 2020; accepted: Sep. 10<sup>th</sup>, 2020; published: Sep. 17<sup>th</sup>, 2020</p><p><img src="//html.hanspub.org/file/21-1571557x6_hanspub.png" /></p></sec><sec id="s4"><title>ABSTRACT</title><p>We hypothesized that the combination of neutrophil to lymphocyte ratio (NLR) and uric acid (UA) is a better predictor of future cardiovascular events after percutaneous coronary intervention (PCI). NLR and UA were measured in 148 consecutive patients undergoing PCI. The primary endpoint was the incidence of major adverse cardiovascular events (MACE), including cardiac death, congestive heart failure, recurrent ischemic attack angina, recurrent myocardial infarction, unplanned revascularization, cardiogenic readmission, and malignant arrhythmia. The median of NLR and UA were 4.89 and 344.71, respectively. During the 12-month follow-up period, there were 45 cases of MACE. Data analysis showed that the MACE rate of higher NLR group and higher UA group was significantly higher than that of lower NLR group and/or lower UA group. The combination of NLR and UA can further improve the prediction accuracy of MACE incidence. This value is particularly useful in patients with acute myocardial infarction (AMI). By multivariate Cox proportional hazard model, the combination of high NLR and high UA was independently associated with MACE (P &lt; 0.05). The combination of high NLR and high UA is an independent predictor of MACE after PCI, especially in patients with AMI.</p><p>Keywords:Neutrophil to Lymphocyte Ratio, Uricacid, Percutaneous Coronary Intervention, MACE</p><disp-formula id="hanspub.37669-formula14"><graphic xlink:href="//html.hanspub.org/file/21-1571557x7_hanspub.png"  xlink:type="simple"/></disp-formula><p>Copyright &#169; 2020 by author(s) and Hans Publishers Inc.</p><p>This work is licensed under the Creative Commons Attribution International License (CC BY 4.0).</p><p>http://creativecommons.org/licenses/by/4.0/</p><p><img src="//html.hanspub.org/file/21-1571557x8_hanspub.png" /> <img src="//html.hanspub.org/file/21-1571557x9_hanspub.png" /></p></sec><sec id="s5"><title>1. 引言</title><p>白细胞(White blood cell, WBC)计数及其成分是心血管疾病(Cardiovascular disease, CVD)中炎症的典型标志 [<xref ref-type="bibr" rid="hanspub.37669-ref1">1</xref>]。中性粒细胞占循环白细胞的60% [<xref ref-type="bibr" rid="hanspub.37669-ref2">2</xref>]。最近的研究表明，中性粒细胞可能在动脉粥样硬化血栓形成中起重要作用，并促进血栓形成 [<xref ref-type="bibr" rid="hanspub.37669-ref3">3</xref>]。同时，越来越多的证据表明，UA水平升高与细胞内氧化应激增强、血管炎症和内皮功能障碍有关，从而导致动脉粥样硬化和心血管疾病的进展 [<xref ref-type="bibr" rid="hanspub.37669-ref4">4</xref>] [<xref ref-type="bibr" rid="hanspub.37669-ref5">5</xref>]。据报道，UA水平升高与富含脂质的斑块、冠状动脉血流储备减少和冠状动脉微血管功能受损有关，这些因素与未来的不良结果有关 [<xref ref-type="bibr" rid="hanspub.37669-ref6">6</xref>]。最近，中性粒细胞与淋巴细胞比率(NLR)被发现是各种心血管疾病中与死亡和不良心脏事件相关的有效全身炎症指标 [<xref ref-type="bibr" rid="hanspub.37669-ref7">7</xref>] [<xref ref-type="bibr" rid="hanspub.37669-ref8">8</xref>]。具体来说，NLR是经皮冠状动脉介入治疗(PCI)患者长期死亡率的预测因子 [<xref ref-type="bibr" rid="hanspub.37669-ref8">8</xref>]。与此同时，UA也被证明和PCI术后的心脏死亡以及主要不良心脏事件有关 [<xref ref-type="bibr" rid="hanspub.37669-ref9">9</xref>]。目前尚不清楚NLR和UA联合应用是否是PCI术后不良事件的更强预测因子。</p></sec><sec id="s6"><title>2. 材料与方法</title><p>1.研究对象：在2017年1月至2019年1月间连续入选并成功PCI的AMI患者均被纳入本研究。ST段抬高性心肌梗死(ST-elevation myocardial infarction, STEMI)被定义为有心肌缺血的特征性症状，与心电图上持续性ST段抬高及随后升高的心肌坏死生物标志物 [<xref ref-type="bibr" rid="hanspub.37669-ref10">10</xref>]。非ST段抬高性心肌梗死(Non-ST-elevation myocardial infarction, NSTEMI)被定义为心肌损伤标志物升高的同时伴有胸部不适或心绞痛，但不伴心电图ST段抬高 [<xref ref-type="bibr" rid="hanspub.37669-ref11">11</xref>]。本研究入选患者资料及血样的采集获得受试者的知情同意，并在我院伦理委员会备案。</p><p>2.排除标准：1) 具有陈旧性心肌梗死，2) 合并全身性疾病、恶性肿瘤、炎症性疾病、急性传染病、严重肝肾功能不全，3) 服用对白细胞(WBC)计数有影响的药物的患者。</p><p>3.观察指标：本研究的终点是指PCI术后12个月内发生主要不良心血管事件(MACE)，包括心源性死亡、充血性心力衰竭、反复缺血性发作性心绞痛、再发心肌梗死、非计划再次血运重建、心源性再次住院、恶性心律失常。心源性死亡是指由任何心脏原因引起的死亡或意外猝死。非计划再次血运重建包括任何冠状动脉手术，包括靶血管重建和靶病变血管重建。</p><p>4.实验室检查：入院时测量全血细胞计数、血脂谱(总胆固醇(TC)、高密度脂蛋白胆固醇(HDL-C)、低密度脂蛋白胆固醇(LDL-C)、甘油三酯(TG)、脂蛋白a(Lpa))、血糖、糖化血清白蛋白(GA)、血清肌酐水平、尿酸、促甲状腺激素(TSH)、N端脑钠肽前体(NT-proBNP)。NLR计算为中性粒细胞与淋巴细胞的比值。收集入院时身高、体重、体重指数、吸烟饮酒史、既往病史、Killip分级和左室射血分数(LVEF)的数据。</p><p>5.统计学方法：连续数据以平均值&#177;标准差表示，分类数据以数量和频率表示。分类变量比较采用卡方检验。连续变量间的差异通过方差分析和假设检验方法进行分析。用受试者操作特性(ROC)曲线设定NLR和UA的临界值，并根据这些值将患者分为3组。不良事件的独立预测因子采用Cox比例风险模型进行评估，包括在单变量分析中p &lt; 0.10水平上与临床结果相关的临床变量。通过似然比检验来确定包含高NLR和高UA的logistic回归模型是否比仅限于高NLR或高UA的logistic回归模型更适合。以P &lt; 0.05 (双侧)为差异有统计学意义。所有统计分析均使用IBM SPSS 22.0。</p></sec><sec id="s7"><title>3. 结果</title><table-wrap-group id="1"><label><xref ref-type="table" rid="table1">Table 1</xref></label><caption><title> Baseline data and laboratory results for the study populatio</title></caption><table-wrap id="1_1"><table><tbody><thead><tr><th align="center" valign="middle" >特征</th><th align="center" valign="middle" >第1组 NLR ≤ 2.54， UA ≤ 448，n = 42</th><th align="center" valign="middle" >第2组 NLR ≤ 2.54，UA &gt; 448或NLR &gt; 2.54， UA ≤ 448，n = 88</th><th align="center" valign="middle" >第3组 NLR &gt; 2.54，UA &gt; 448，n = 18</th><th align="center" valign="middle" >P</th></tr></thead><tr><td align="center" valign="middle" >年龄(岁)</td><td align="center" valign="middle" >63.6 &#177; 11.8</td><td align="center" valign="middle" >63.7 &#177; 12.2</td><td align="center" valign="middle" >64.8 &#177; 13.3</td><td align="center" valign="middle" >0.933</td></tr><tr><td align="center" valign="middle" >男性(%)</td><td align="center" valign="middle" >31 (27.9)</td><td align="center" valign="middle" >66 (59.5)</td><td align="center" valign="middle" >14 (12.6)</td><td align="center" valign="middle" >0.948</td></tr><tr><td align="center" valign="middle" >BMI</td><td align="center" valign="middle" >25.0 &#177; 3.6</td><td align="center" valign="middle" >25.6 &#177; 3.3</td><td align="center" valign="middle" >26.1 &#177; 4.4</td><td align="center" valign="middle" >0.467</td></tr><tr><td align="center" valign="middle" >吸烟史</td><td align="center" valign="middle" >24 (28.9)</td><td align="center" valign="middle" >49 (59.0)</td><td align="center" valign="middle" >10 (12.0)</td><td align="center" valign="middle" >0.987</td></tr><tr><td align="center" valign="middle" >饮酒史</td><td align="center" valign="middle" >16 (30.8)</td><td align="center" valign="middle" >31 (59.6)</td><td align="center" valign="middle" >5 (9.6)</td><td align="center" valign="middle" >0.745</td></tr><tr><td align="center" valign="middle" >糖尿病史</td><td align="center" valign="middle" >14 (31.8)</td><td align="center" valign="middle" >25 (56.8)</td><td align="center" valign="middle" >5 (11.4)</td><td align="center" valign="middle" >0.832</td></tr><tr><td align="center" valign="middle" >高血压病史</td><td align="center" valign="middle" >26 (27.4)</td><td align="center" valign="middle" >54 (56.8)</td><td align="center" valign="middle" >15 (15.8)</td><td align="center" valign="middle" >0.195</td></tr><tr><td align="center" valign="middle" >NT-ProBNP (pg/ml)</td><td align="center" valign="middle" >565.1 &#177; 795.9</td><td align="center" valign="middle" >1547 &#177; 2158.7</td><td align="center" valign="middle" >3830.5 &#177; 6171.4</td><td align="center" valign="middle" >0.001<sup>a</sup></td></tr><tr><td align="center" valign="middle" >LDL-C (mmol/L)</td><td align="center" valign="middle" >2.7 &#177; 0.9</td><td align="center" valign="middle" >2.9 &#177; 0.8</td><td align="center" valign="middle" >3.9 &#177; 0.8</td><td align="center" valign="middle" >0.290</td></tr><tr><td align="center" valign="middle" >TC (mmol/L)</td><td align="center" valign="middle" >4.5 &#177; 1.1</td><td align="center" valign="middle" >4.8 &#177; 1.0</td><td align="center" valign="middle" >5.0 &#177; 1.0</td><td align="center" valign="middle" >0.153</td></tr><tr><td align="center" valign="middle" >TG (mmol/L)</td><td align="center" valign="middle" >2.0 &#177; 1.3</td><td align="center" valign="middle" >1.9 &#177; 2.3</td><td align="center" valign="middle" >2.1 &#177; 1.6</td><td align="center" valign="middle" >0.899</td></tr></tbody></table></table-wrap><table-wrap id="1_2"><table><tbody><thead><tr><th align="center" valign="middle" >GA (mmol/L)</th><th align="center" valign="middle" >14.9 &#177; 5.7</th><th align="center" valign="middle" >14.2 &#177; 4.4</th><th align="center" valign="middle" >12.9 &#177; 3.6</th><th align="center" valign="middle" >0.332</th></tr></thead><tr><td align="center" valign="middle" >HDL-C (mmol/L)</td><td align="center" valign="middle" >1.12 &#177; 0.3</td><td align="center" valign="middle" >1.15 &#177; 0.3</td><td align="center" valign="middle" >1.1 &#177; 0.3</td><td align="center" valign="middle" >0.689</td></tr><tr><td align="center" valign="middle" >Lpa (mmol/L)</td><td align="center" valign="middle" >305.2 &#177; 288.1</td><td align="center" valign="middle" >289.1 &#177; 262.2</td><td align="center" valign="middle" >231.3 &#177; 133.6</td><td align="center" valign="middle" >0.593</td></tr><tr><td align="center" valign="middle" >Neut# (10^9/L)</td><td align="center" valign="middle" >4.3 &#177; 1.1</td><td align="center" valign="middle" >7.6 &#177; 2.4</td><td align="center" valign="middle" >10.0 &#177; 5.7<sup>b</sup></td><td align="center" valign="middle" >&lt;0.001<sup> a</sup></td></tr><tr><td align="center" valign="middle" >Lymph# (10^9/L)</td><td align="center" valign="middle" >2.3 &#177; 0.6</td><td align="center" valign="middle" >1.6 &#177; 0.6</td><td align="center" valign="middle" >1.5 &#177; 0.6<sup>b</sup></td><td align="center" valign="middle" >&lt;0.001<sup> a</sup></td></tr><tr><td align="center" valign="middle" >NLR</td><td align="center" valign="middle" >1.9 &#177; 0.4</td><td align="center" valign="middle" >5.7 &#177; 3.6</td><td align="center" valign="middle" >7.7 &#177; 4.9<sup>b</sup></td><td align="center" valign="middle" >&lt;0.001<sup> a</sup></td></tr><tr><td align="center" valign="middle" >UA (μmol/L)</td><td align="center" valign="middle" >310.1 &#177; 80.2</td><td align="center" valign="middle" >322.8 &#177; 93.1</td><td align="center" valign="middle" >532.4 &#177; 78.5<sup>bc</sup></td><td align="center" valign="middle" >&lt;0.001<sup> a</sup></td></tr><tr><td align="center" valign="middle" >TSH (mIU/L)</td><td align="center" valign="middle" >4.3 &#177; 13.5</td><td align="center" valign="middle" >3.1 &#177; 8.0</td><td align="center" valign="middle" >1.6 &#177; 1.5</td><td align="center" valign="middle" >0.584</td></tr><tr><td align="center" valign="middle" >住院天数 (天)</td><td align="center" valign="middle" >8.0 &#177; 2.7</td><td align="center" valign="middle" >8.6 &#177; 4.5</td><td align="center" valign="middle" >11.9 &#177; 7.2</td><td align="center" valign="middle" >0.072</td></tr><tr><td align="center" valign="middle" >心功能分级</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" >0.448</td></tr><tr><td align="center" valign="middle" >I</td><td align="center" valign="middle" >32 (32.7)</td><td align="center" valign="middle" >57 (58.2)</td><td align="center" valign="middle" >9 (9.1)</td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >II</td><td align="center" valign="middle" >8 (25.8)</td><td align="center" valign="middle" >18 (58.1)</td><td align="center" valign="middle" >5 (16.1)</td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >III</td><td align="center" valign="middle" >1 (20)</td><td align="center" valign="middle" >3 (60)</td><td align="center" valign="middle" >1 (20)</td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >IV</td><td align="center" valign="middle" >1 (7.2)</td><td align="center" valign="middle" >10 (71.4)</td><td align="center" valign="middle" >3 (21.4)</td><td align="center" valign="middle" ></td></tr></tbody></table></table-wrap></table-wrap-group><p>表1. 研究人群的基线数据及实验室结果</p><p><sup>a</sup>p &lt; 0.05，差别有统计学意义；<sup>b</sup>与第一组相比p &lt; 0.05；<sup>c</sup>与第二组相比p &lt; 0.05。</p><p>本研究共纳入148例患者，随访失败的患者被排除在分析之外。148例患者中，男性75%，平均年龄63.79 &#177; 12.15岁，均接受PCI治疗，随访1年。表1为研究人群的基线资料，其中吸烟：按WHO吸烟调查标准规定：每天吸烟≥一支，连续吸烟一年以上，长期吸烟但戒烟短于半年者为吸烟史阳性。饮酒：连续饮酒超过1年为饮酒史阳性。LDL-C：低密度脂蛋白胆固醇。TC：总胆固醇。TG：甘油三酯。GA：糖化血清白蛋白。HDL-C：高密度脂蛋白胆固醇。Lpa：脂蛋白a。Neut#：中性粒细胞。Lymph#：淋巴细胞。NLR：中性粒细胞与淋巴细胞比值。UA：尿酸。TSH：促甲状腺激素。</p><p>在ROC分析中，NLR和UA预测12个月主要心血管不良事件的最佳临界值是曲线下最大的面积。NLR和UA的临界值分别为2.54 (ROC曲线下的面积[AUC] = 0.81，灵敏度 = 73.3%，特异性 = 76.7%，p &lt; 0.001)和448 (AUC = 0.737，灵敏度 = 57.8％，特异性 = 88.3%，p &lt; 0.001，见图1)。NLR和UA均符合正态分布，采用pearson相关性分析，结果示：在NLR和UA之间不存在相关性(r = 0.096, P = 0.245)，可能是由于样本量不足导致的(见图2)。根据NLR和UA的最佳临界值将患者分为3组：低NLR和低UA (第1组，NLR ≤ 2.54，UA ≤ 448，n = 42)，低NLR和高UA或高NLR和低UA (第2组，NLR ≤ 2.54，UA &gt; 448或NLR &gt; 2.54，UA ≤ 448，n = 88)，高NLR和高UA (第3组，NLR &gt; 2.54，UA &gt; 448，n = 18)。</p><p>与其他组相比，第3组的患者NT-ProBNP水平较高。我们总结了12个月时的临床结果(见表2)。与其他组相比，第3组患者的MACE发生率显著升高(第3组为83.3%，第1组为0%，第2组为34.1%，p &lt; 0.001)。在Cox回归单因素分析中，年龄、女性、糖尿病、吸烟史、高血压病史、LVEF、NLR、UA和联合NLR-UA是12个月发生MACE的显著预测因子。多元分析发现，高NLR &gt; 2.54和高UA &gt; 448是12个月发生MACE的独立预测因子，高NLR和高UA的组合是最佳的预测因子。在似然比检验中，比较使用高NLR和高UA的预测模型与单独使用高NLR或高UA的模型的拟合，这两个参数的联合评估显著提高了发生MACE风险的预测能力(见图3)。</p><p>图1. 12个月发生MACE时UA和NLR的ROC曲线</p><p>图2. NLR和UA的相关性分析</p><p>图3. 各组发生MACE的例数</p><table-wrap id="table2" ><label><xref ref-type="table" rid="table2">Table 2</xref></label><caption><title> Clinical results of the study population at 12 months based on NLR and U</title></caption><table><tbody><thead><tr><th align="center" valign="middle" >组别</th><th align="center" valign="middle" >n</th><th align="center" valign="middle" >主要心血管不良事件</th></tr></thead><tr><td align="center" valign="middle" >第1组</td><td align="center" valign="middle" >42</td><td align="center" valign="middle" >0 (0%)<sup>b</sup></td></tr><tr><td align="center" valign="middle" >第2组</td><td align="center" valign="middle" >88</td><td align="center" valign="middle" >30 (34.1%)<sup>c</sup></td></tr><tr><td align="center" valign="middle" >第3组</td><td align="center" valign="middle" >18</td><td align="center" valign="middle" >15 (83.3%)<sup>bc</sup></td></tr><tr><td align="center" valign="middle" >P</td><td align="center" valign="middle" >-</td><td align="center" valign="middle" >&lt;0.001 a</td></tr></tbody></table></table-wrap><p>表2. 根据NLR和UA，研究人群12个月时的临床结果</p><p><sup>b</sup>与第一组相比p &lt; 0.05；<sup>c</sup>与第二组相比p &lt; 0.05；-表示无数据。</p></sec><sec id="s8"><title>4. 讨论</title><p>在148例接受PCI治疗的AMI患者中，我们发现入院时NLR和UA的联合参数升高与发生MACE的风险增加有关。据我们所知，这是首次分析NLR和UA联合应用对AMI患者PCI术后远期预后的预测价值。近年来，随着炎症状态对心肌梗死发生和发展的影响越来越受到重视，许多研究集中在炎症生物标志物与AMI患者不良临床结局之间的关系上。这项研究的结果与最近发表的数据相一致，这些数据表明高NLR或UA与AMI患者的不良临床结果之间存在关联 [<xref ref-type="bibr" rid="hanspub.37669-ref12">12</xref>] [<xref ref-type="bibr" rid="hanspub.37669-ref13">13</xref>]。一些研究人员发现，使用NLR或UA预测AMI的进展和预后是可能的，但综合应用NLR和UA作为AMI的预测因子在以往的研究中还没有被研究过。</p><p>既往一项研究显示，高NLR与心脏不良事件的风险增加密切相关 [<xref ref-type="bibr" rid="hanspub.37669-ref14">14</xref>]。这种联系的一个可能的假设是中性粒细胞在心肌急性损伤时作为炎症反应的介质发挥作用 [<xref ref-type="bibr" rid="hanspub.37669-ref15">15</xref>]，因为它们会释放一些生化物质，如活性氧和蛋白水解酶 [<xref ref-type="bibr" rid="hanspub.37669-ref16">16</xref>]。另一方面，由于炎症引起的细胞凋亡，淋巴细胞减少 [<xref ref-type="bibr" rid="hanspub.37669-ref17">17</xref>]。因此，高NLR提示心肌梗死的进一步风险。同时，越来越多的实验研究表明UA与动脉粥样硬化和心血管疾病的发生和发展有关。细胞内和线粒体内的UA被证明释放自由基并诱导氧化应激，导致动脉粥样硬化的增强 [<xref ref-type="bibr" rid="hanspub.37669-ref18">18</xref>]。UA还可能通过刺激趋化因子的表达，如单核细胞趋化蛋白-1，从而诱导血管炎症 [<xref ref-type="bibr" rid="hanspub.37669-ref19">19</xref>] [<xref ref-type="bibr" rid="hanspub.37669-ref20">20</xref>]。此外，UA已被证明与一氧化氮可用性降低相关，从而导致内皮功能障碍 [<xref ref-type="bibr" rid="hanspub.37669-ref21">21</xref>]。另外，一些临床研究将UA与冠状动脉疾病联系在一起，比如Saito和同事的一份报告显示UA与富含脂质的冠状动脉斑块之间存在相关性，后者被认为是未来发生心血管病事件的前兆 [<xref ref-type="bibr" rid="hanspub.37669-ref6">6</xref>]。颈动脉斑块也有类似的发现 [<xref ref-type="bibr" rid="hanspub.37669-ref22">22</xref>]。同时，UA与冠状动脉粥样硬化程度、冠状动脉血流储备减少和冠状动脉微血管功能受损有关 [<xref ref-type="bibr" rid="hanspub.37669-ref23">23</xref>]。Pagidipati等人最近发表的一项研究可以证明UA与短期不良结果的显著关联 [<xref ref-type="bibr" rid="hanspub.37669-ref24">24</xref>]。</p><p>几乎所有的胸痛病人入院时都常规行全血细胞及肾功能检测，价格便宜，并且可以在大约1小时内得到结果。由于急性胸痛患者在常规实验室检查中容易获得NLR和UA，因此用这些生物标志物预测AMI患者的预后可能比其他生物标志物更容易、更舒适。尽管我们研究了联合应用NLR和UA是否比NLR或UA更能预测临床预后，但在一些研究中，这两个参数已经被描述为心血管疾病患者预后不良的预测因子；因此，我们可以说这两个生物标志物的结合并不是新的。然而，我们认为，如果在接受PCI治疗的AMI患者中，联合使用这两个参数可以更好地指导医生做出更好的临床决策。如果在现有模型的基础上加上这些值来监测AMI患者的预后，这些模型的效率和准确性将会提高。此外，一个更好的先发制人的计划和更明确的方向的治疗过程将有助于更好的治疗效果，患者的依从性可能会提高。但根据相关性分析，在NLR和UA之间不存在相关性(r = 0.096, P = 0.245)，可能是因为本研究纳入样本量不足导致的。</p><p>总之，NLR和UA在AMI中的病理生理作用尚未揭示，还需要进一步的研究来补充这些未知的方面。以及临床上给予药物降低NLR和UA是否会改善AMI患者PCI术后的预后仍缺乏研究。</p></sec><sec id="s9"><title>文章引用</title><p>徐宝丽,李 喆,管甲亮,臧守亚,刘艳伟,李 菁,王星月,周长勇. UA、NLR对急性心肌梗死患者PCI术后预后的判断价值的研究The Value of UA NLR in Predicting the Prognosis of Patients with Acute Myocardial Infarction after PCI[J]. 临床医学进展, 2020, 10(09): 2009-2016. https://doi.org/10.12677/ACM.2020.109301</p></sec><sec id="s10"><title>参考文献</title></sec></body><back><ref-list><title>References</title><ref id="hanspub.37669-ref1"><label>1</label><mixed-citation publication-type="other" xlink:type="simple">Horne, B.D., Anderson, J.L., John, J.M., et al. (2005) Which White Blood Cell Subtypes Predict Increased Cardiovascular Risk? Journal of the American College of Cardiology, 45, 1638-1643. 
&lt;br&gt;https://doi.org/10.1016/j.jacc.2005.02.054</mixed-citation></ref><ref id="hanspub.37669-ref2"><label>2</label><mixed-citation publication-type="other" xlink:type="simple">Murphy, A.J. and Tall, A.R. (2016) Disordered Haematopoiesis and Athero-Thrombosis. European Heart Journal, 37, 1113-1121. &lt;br&gt;https://doi.org/10.1093/eurheartj/ehv718</mixed-citation></ref><ref id="hanspub.37669-ref3"><label>3</label><mixed-citation publication-type="other" xlink:type="simple">Warnatsch, A., Ioannou, M., Wang, Q. and Papayannopoulos, V. (2015) Inflammation. Neutrophil Extracellular Traps License Macrophages for Cytokine Production in Atherosclerosis. Science, 349, 316-320.  
&lt;br&gt;https://doi.org/10.1126/science.aaa8064</mixed-citation></ref><ref id="hanspub.37669-ref4"><label>4</label><mixed-citation publication-type="other" xlink:type="simple">Kanbay, M., Siriopol, D., Nistor, I., Elcioglu, O.C., Telci, O., Takir, M., Johnson, R.J. and Covic, A. (2014) Effects of Allopurinol on Endothelial Dysfunction: A Meta-Analysis. American Journal of Nephrology, 39, 348-356.  
&lt;br&gt;https://doi.org/10.1159/000360609</mixed-citation></ref><ref id="hanspub.37669-ref5"><label>5</label><mixed-citation publication-type="other" xlink:type="simple">Yu, M.A., Sanchez-Lozada, L.G., Johnson, R.J. and Kang, D.-H. (2010) Oxidative Stress with an Activation of the Renin-Angiotensin System in Human Vascular Endothelial Cells as a Novel Mechanism of Uric Acid-Induced Endothelial Dysfunction. Journal of Hypertension, 28, 1234-1242. &lt;br&gt;https://doi.org/10.1097/HJH.0b013e328337da1d</mixed-citation></ref><ref id="hanspub.37669-ref6"><label>6</label><mixed-citation publication-type="other" xlink:type="simple">Saito, Y., Nakayama, T., Sugimoto, K., Fujimoto, Y. and Kobayashi, Y. (2015) Relation of Lipid Content of Coronary Plaque to Level of Serum Uric Acid. The American Journal of Cardiology, 116, 1346-1350.  
&lt;br&gt;https://doi.org/10.1016/j.amjcard.2015.07.059</mixed-citation></ref><ref id="hanspub.37669-ref7"><label>7</label><mixed-citation publication-type="other" xlink:type="simple">Kim, S.C., Sun, K.H., Choi, D.H., et al. (2016) Prediction of Long-Term Mortality Based on Neutrophil-Lymphocyte Ratio after Percutaneous Coronary Intervention. The American Journal of the Medical Sciences, 351, 467-472.  
&lt;br&gt;https://doi.org/10.1016/j.amjms.2015.12.022</mixed-citation></ref><ref id="hanspub.37669-ref8"><label>8</label><mixed-citation publication-type="other" xlink:type="simple">Cho, K.H., Jeong, M.H., Ahmed, K., et al. (2011) Value of Early Risk Stratification Using Hemoglobin Level and Neutrophil-to-Lymphocyte Ratio in Patients with ST-Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention. The American Journal of Cardiology, 107, 849-856. 
&lt;br&gt;https://doi.org/10.1016/j.amjcard.2010.10.067</mixed-citation></ref><ref id="hanspub.37669-ref9"><label>9</label><mixed-citation publication-type="other" xlink:type="simple">Lazzeri, C., Valente, S., Chiostri, M., Sori, A., Bernardo, P. and Gensini, G.F. (2010) Uric Acid in the Acute Phase of ST Elevation Myocardial Infarction Submitted to Primary PCI: Its Prognostic Role and Relation with Inflammatory Markers: A Single Center Experience. International Journal of Cardiology, 138, 206-209. 
&lt;br&gt;https://doi.org/10.1016/j.ijcard.2008.06.024</mixed-citation></ref><ref id="hanspub.37669-ref10"><label>10</label><mixed-citation publication-type="other" xlink:type="simple">中华医学会心血管病学分会, 中华心血管病杂志编辑委员会. 急性ST段抬高型心肌梗死诊断和治疗指南(2019) [J]. 中华心血管病杂志, 2019(10): 766-767.</mixed-citation></ref><ref id="hanspub.37669-ref11"><label>11</label><mixed-citation publication-type="other" xlink:type="simple">Amsterdam, E.A., Wenger, N.K., Brindis, R.G., et al. (2014) 2014 AHA/ACC Guideline for the Management of Patients with Non-ST-Elevation Acute Coronary Syndromes: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Journal of the American College of Cardiology, 64, e139-e228.  
&lt;br&gt;https://doi.org/10.1161/CIR.0000000000000134</mixed-citation></ref><ref id="hanspub.37669-ref12"><label>12</label><mixed-citation publication-type="other" xlink:type="simple">Tamhane U U, Aneja S, Montgomery D, Rogers, E.-K., Eagle, K.A. and Gurm, H.S. (2008) Association between Admission Neutrophil to Lymphocyte Ratio and Outcomes in Patients with Acute Coronary Syndrome. The American Journal of Cardiology, 102, 653-657. &lt;br&gt;https://doi.org/10.1016/j.amjcard.2008.05.006</mixed-citation></ref><ref id="hanspub.37669-ref13"><label>13</label><mixed-citation publication-type="other" xlink:type="simple">Azab, B., Zaher, M., Weiserbs, K.F., et al. (2010) Usefulness of Neutrophil to Lymphocyte Ratio in Predicting Short- and Long-Term Mortality after Non-ST-Elevation Myocardial Infarction. The American Journal of Cardiology, 106, 470-476. &lt;br&gt;https://doi.org/10.1016/j.amjcard.2010.03.062</mixed-citation></ref><ref id="hanspub.37669-ref14"><label>14</label><mixed-citation publication-type="other" xlink:type="simple">Fowler, A.J. and Agha, R.A. (2013) Neutrophil/Lymphocyte Ratio Is Related to the Severity of Coronary Artery Disease and Clinical Outcome in Patients Undergoing Angiography—The Growing Versatility of NLR. Atherosclerosis, 228, 44-45. &lt;br&gt;https://doi.org/10.1016/j.atherosclerosis.2013.02.008</mixed-citation></ref><ref id="hanspub.37669-ref15"><label>15</label><mixed-citation publication-type="other" xlink:type="simple">Keeley, E.C., Boura, J.A. and Grines, C.L. (2003) Primary Angioplasty versus Intravenous Thrombolytic Therapy for Acute Myocardial Infarction: A Quantitative Review of 23 Randomised Trials. The Lancet, 361, 13-20. 
&lt;br&gt;https://doi.org/10.1016/S0140-6736(03)12113-7</mixed-citation></ref><ref id="hanspub.37669-ref16"><label>16</label><mixed-citation publication-type="other" xlink:type="simple">Frangogiannis, N.G. (2019) Cardiac Fibrosis: Cell Biological Mechanisms, Molecular Pathways and Therapeutic Opportunities. Molecular Aspects of Medicine, 65, 70-99. &lt;br&gt;https://doi.org/10.1016/j.mam.2018.07.001</mixed-citation></ref><ref id="hanspub.37669-ref17"><label>17</label><mixed-citation publication-type="other" xlink:type="simple">Thygesen, K., Alpert, J.S., Jaffe, A.S., et al. (2018) Fourth Universal Definition of Myocardial Infarction (2018). Journal of the American College of Cardiology, 72, 2231-2264. &lt;br&gt;https://doi.org/10.1016/j.jacc.2018.08.1038</mixed-citation></ref><ref id="hanspub.37669-ref18"><label>18</label><mixed-citation publication-type="other" xlink:type="simple">Forstermann, U., Xia, N. and Li, H. (2017) Roles of Vascular Oxidative Stress and Nitric Oxide in the Pathogenesis of Atherosclerosis. Circulation Research, 120, 713-735. &lt;br&gt;https://doi.org/10.1161/CIRCRESAHA.116.309326</mixed-citation></ref><ref id="hanspub.37669-ref19"><label>19</label><mixed-citation publication-type="other" xlink:type="simple">Prasad, M., Matteson, E.L., Herrmann, J., Gulati, R., Rihal, C.S., Lerman, L.O. and Lerman, A. (2017) Uric Acid Is Associated with Inflammation, Coronary Microvascular Dysfunction, and Adverse Outcomes in Postmenopausal Women. Hypertension, 69, 236-242. &lt;br&gt;https://doi.org/10.1161/HYPERTENSIONAHA.116.08436</mixed-citation></ref><ref id="hanspub.37669-ref20"><label>20</label><mixed-citation publication-type="other" xlink:type="simple">Kang, D.H., Park, S.K., Lee, I.K. and Johnson, R.J. (2005) Uric Acid-Induced C-Reactive Protein Expression: Implication on Cell Proliferation and Nitric Oxide Production of Human Vascular Cells. Journals of the American Society of Nephrology, 16, 3553-3562. &lt;br&gt;https://doi.org/10.1681/ASN.2005050572</mixed-citation></ref><ref id="hanspub.37669-ref21"><label>21</label><mixed-citation publication-type="other" xlink:type="simple">Wardhana, W. and Rudijanto, A. (2018) Effect of Uric Acid on Blood Glucose Levels. Acta Medica Indonesiana, 50, 253-256.</mixed-citation></ref><ref id="hanspub.37669-ref22"><label>22</label><mixed-citation publication-type="other" xlink:type="simple">Li, Q., Zhou, Y., Dong, K.H., et al. (2015) The Association between Serum Uric Acid Levels and the Prevalence of Vulnerable Atherosclerotic Carotid Plaque: A Cross-Sectional Study. Scientific Reports, 5, Article No. 10003. 
&lt;br&gt;https://doi.org/10.1038/srep10003</mixed-citation></ref><ref id="hanspub.37669-ref23"><label>23</label><mixed-citation publication-type="other" xlink:type="simple">Ahmad, Y., Vendrik, J., Eftekhari, A., et al. (2019) Determining the Predominant Lesion in Patients with Severe Aortic Stenosis and Coronary Stenoses: A Multicenter Study Using Intracoronary Pressure and Flow. Circulation: Cardiovascular Interventions, 12, e8263. &lt;br&gt;https://doi.org/10.1161/CIRCINTERVENTIONS.119.008263</mixed-citation></ref><ref id="hanspub.37669-ref24"><label>24</label><mixed-citation publication-type="other" xlink:type="simple">Pagidipati N J, Hess C N, Clare R M, et al. (2017) An Examination of the Relationship between Serum Uric Acid Level, a Clinical History of Gout, and Cardiovascular Outcomes among Patients with Acute Coronary Syndrome. American Heart Journal, 187, 53-61. &lt;br&gt;https://doi.org/10.1016/j.ahj.2017.02.023</mixed-citation></ref></ref-list></back></article>